



Edwin Melencio Posadas, MD, FACP, KM

CURRICULUM VITAE

December 2016

**Professional Contact Information:** 8700 Beverly Blvd  
Los Angeles CA 90048  
(310) 423-7600  
Edwin.Posadas@csmc.edu

**Education:** B.E.S. Biomedical Engineering, Johns Hopkins University- 1993  
B.E.S. Chemical Engineering, Johns Hopkins University- 1993  
- General and departmental honors (summa cum laude) from both departments  
- Emphasis on biological transport systems and physiological fluid mechanics  
  
M.D. Johns Hopkins University School of Medicine. 1998  
  
Internship/Residency: University of Michigan Medical Center 2001  
  
Fellowship: National Cancer Institute & National Heart, Lung, and Blood Institute- 2005

**Licensure:** California C54501

**Board Certification:** Internal Medicine (2001)  
Medical Oncology (2007)

**Professional Experience:** Director, Translational Oncology Program  
Samuel Oschin Comprehensive Cancer Institute  
Cedar Sinai Medical Center  
January 2016 – present

Medical Director, Urologic Oncology Program  
Samuel Oschin Comprehensive Cancer Institute  
Cedar Sinai Medical Center  
March 2011 – present

Associate Professor, Department of Medicine  
Cedars Sinai Medical Center  
July 2014 - present

Health Sciences Associate Clinical Professor, Step I, Department of Medicine  
University of California at Los Angeles  
July 2014 - present

Assistant Professor, Department of Medicine  
Cedars Sinai Medical Center  
January 2012 – July 2014

Health Sciences Assistant Clinical Professor, Department of Medicine  
University of California at Los Angeles  
August 2011 – July 2014

Assistant Professor, Department of Medicine, Section of Hematology/Oncology  
Assistant Professor, Department of Surgery, Section of Urology  
University of Chicago  
June 2007 – March 2011

Instructor, Department of Medicine, Section of Hematology/Oncology  
University of Chicago  
May 2005 – June 2007

**Professional  
Activities:**

Professional Associations and Scholarly Societies:

American Medical Association - Member  
American Society of Clinical Oncology- Member  
American Association for Cancer Research- Member  
American College of Physicians- Member & Fellow  
American Urological Association- Affiliate Member  
Society of Basic Urologic Research- Member  
Association of Philippine Physicians of America - Member  
National Catholic Center for Bioethics - Member  
Catholic Medical Association – Member  
Cancer and Leukemia Group B- Member GU Oncology Committee (2006-2011)  
Society of Basic Urologic Research – Member  
Western Section, American Urological Association- Affiliate Member  
Southwestern Oncology Group- Member GU Oncology Committee  
American Society for Therapeutic Radiation Oncology- Member  
Radiation Therapy Oncology Group- Member GU Oncology Committee &  
Translational Research Program  
European Society of Medical Oncology- Member  
Blood Profiling Atlas in Cancer- Cancer Moonshot Program- Member  
Society of Catholic Scientists- Member

Committee Service:

2009-2011 Cancer Education Committee: American Society of Clinical Oncology  
2008-2011 Clinical Trials Review Committee: University of Chicago  
2006-2008 Heme/Onc Inpatient Flow Director- University of Chicago  
2012- 2013 Physician Engagement Team- American Cancer Society  
2012 Prostate Cancer Foundation Young Investigators' Retreat Planning  
Committee  
2013-2017 American Cancer Society- Community Leadership Council  
2015 Planning Committee: Urologic Association of Asia

National/International Scientific Review Committees

2004 US Department of Defense: CDMRP- Prostate Cancer Cell Biology  
Review Committee  
2006 Italian Association for Cancer Research (AICR)  
2006-2008 US Department of Defense: CDMRP- Ovarian Cancer Cell Biology  
Review Committee  
2008- 2012 US Department of Defense: CDMRP- Prostate Cancer Training Awards  
Review Committee  
2013-2014 US Department of Defense: CDMRP- Health Disparities Review  
Committee

Consultation Positions

2011-Present Prostate Cancer Foundation Special Consultant: IBM Watson project

Journal Affiliations:

2012- Present Editorial Board- World Journal of Clinical Case Conference  
2010- Current Editorial board: Anticancer Agents in Medicinal Chemistry  
2009- Current Editorial board: European Journal of Clinical and Medical Oncology

2015- Current Editorial board: Advances in Modern Oncology Research  
 2016- Current Editorial board: Urological Cancers  
 2016 Guest Editor: Asian Journal of Urology  
 2016 Guest Editor: Kidney Cancer Journal  
 2004- Present Reviewer: Cancer  
 2005- Present Reviewer: Molecular & Cellular Proteomics  
 2005- Present Reviewer: Journal of Proteome Research  
 2005- Present Reviewer: Cancer Research  
 2005- Present Reviewer: Clinical Cancer Research  
 2006- Present Reviewer: Cancer Immunology Immunotherapy  
 2006- Present Reviewer: The Prostate  
 2007- Present Reviewer: Clinical Prostate Cancer  
 2007- Present Reviewer: Cancer Chemotherapy and Pharmacology  
 2009- Present Reviewer: Urology  
 2014- Present Reviewer: Prostate Cancer and Prostatic Disease  
 2015- Present Reviewer: Journal of Clinical Oncology  
 2015- Present Reviewer: Urologic Oncology  
 2015- Present Reviewer: Journal of Pathology

**CSMC Professional Activities:**

**Committee Service:**

2011-2013 Urologic Oncology COE, Medical Director  
 2011-Present Protocol Review Committee, Member  
 2011-2012 Medical Staff Leadership Program, Participant  
 2011-Present Cancer Quality Committee, Member  
 2011-Present Urologic Oncology Program, Medical Director  
 2012-Present Cancer Committee, Member  
 2014-2016 Clinical co-Chief, Division of Hematology/Oncology  
 2016-Present Director, Translational Oncology Program

**Honors and Special Awards:**

Summer 1991 National Science Foundation Summer Research Fellowship  
 Spring 1992 Golden Key National Honors Society (Inducted)  
 Spring 1992 Tau Beta Pi national Engineering Honors Society (Inducted)  
 Spring 1992 JHU Department of Chemical Engineering Paul A.C. Cook Award  
 Spring 1992 Biomedical Engineering Award  
 Summer 1992 American Chemical Society Polymer Division Summer Research Scholarship  
 Spring 1993 JHU Department of Biomedical Engineering Distinguished Service Award  
 May 2003 ASCO Travel Grant Award Recipient- Best of ASCO 2003  
 March 2004 AACR/NOCC Scholar-in-Training Award  
 July 2004 AACR Methods in Clinical Oncology Workshop 2004- Aspen, CO  
 Sept 2004 Martha Rivkin Foundation for Ovarian Cancer- Travel Award  
 March 2010 Fellow: American College of Physicians  
 November 2011 Member: Sovereign Military Hospitaller Order of Saint John of Jerusalem of Rhodes and of Malta  
 May 2012 Member: Bureau des Constatations Médicales- Lourdes, France  
 August 2014 International Association of Internists: Top Internist Award  
 August 2014 International Association of Oncologists: Top Oncologist Award  
 March 2016 Leading physicians of the world: Top Doctor- Los Angeles CA  
 March 2016 Scientific Advisory Board: Tower Cancer Research Foundation

**Fellowships Received:**

American College of Physicians, Fellow (March 2010)

**Research Grants Active Support**

NCI 1U01CA198900-01 (role: co-Principal Investigator)  
 Thermoresponsive NanoVelcro CTC Purification System for Prostate Cancer Profiling  
 2015/08/16-2020/07/30 (PIs: Tseng & Posadas)

NIH/NCI 5P01CA098912 (role: co-investigator)  
Prostate cancer bone metastasis: biology and targeting (PI: Chung)  
12/1/02-4/30/19  
\$1,454,096

Pfizer (role: PI)  
Blood biomarkers in renal cell carcinoma  
12/12/16 – 1/1/2019

### Completed Support

Spielberg Family Foundation Research Award (role: co-investigator)  
The ecosystem of lethal prostate cancer (PI: Knudsen)  
10/1/2013 – 10/1/2015  
\$1,600,000

Margaret Early Family Trust (role: co-investigator)  
Untangling mitochondrial MAOA and nuclear AR communication for the management of lethal castration-resistant prostate cancer metastasis (PI: Chung)  
1/1/2015-12/31/2015  
\$75,000

NIH/NCI 5P01CA098912 (role: co-investigator)  
Prostate cancer bone metastasis: biology and targeting (PI: Chung)  
12/1/02-7/31/15  
\$1,454,096

Department of Defense/CDMRP Idea Award (role: PI)  
Fyn is a key regulator of metastasis in prostate cancer  
Approved- 5/15/2011-6/1/2015  
\$450,000 - Direct, \$720,000 - Indirect  
6% Effort  
PC100368

Prostate Cancer Foundation/ Challenge Award (role: co-investigator)  
Microenvironmental interactions in prostate cancer (PI: L. Chung)  
7/1/2011 – 7/31/2013  
\$400,000/year x 2 years  
5% effort

Prostate Cancer Foundation/ Challenge Award (role: co-PI)  
Understanding the clinical and radiological impacts of XL184 through treatment science (PIs: Posadas/Higano)  
7/1/2011 – 8/31/2015  
\$1,000,000

Prostate Cancer Foundation/ Young Investigator Award (role: PI)  
Fyn: a key regulator of metastasis in prostate cancer  
7/1/2010 – 6/30/2013  
\$450,000

Department of Defense/CDMRP Physician Research Training Award (role: PI)  
FYN: a regulator of growth and motility and prostate cancer  
4/1/08/ - 4/1/11 – entering no-cost extension in transfer to CSMC  
\$417,576  
50 % Effort  
PC073540 – W81XWH-08-1-0470

Rivera Foundation  
Molecular therapeutics in Prostate Cancer 1/1/06 - 1/1/07 \$24,000

University of Chicago Auxiliary Board 1/1/06 – 12/30/08 \$35,000  
Targeted Therapy in Prostate Cancer

Training sub award from Prostate SPORE- Chicago SPORE consortium (role PI)  
FYN: a novel target in advanced prostate cancer 5/1/09 – 5/1/10

\$40,000

## Research Projects:

### Clinical Research:

#### Prostate Cancer

##### Past:

1. CALGB 90203: Randomized Phase III Study Of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior To Radical Prostatectomy Versus Immediate Radical Prostatectomy In Patients With High Risk, Clinically Localized Prostate Cancer. Local PI (University of Chicago).
2. Factors Predicting the Decision to Initiate Androgen Deprivation Therapy and Consequential Advancement to Frailty. Co-Investigator.
3. Effect of Dutasteride on Androgen-Response Gene Expression During the Tumor Regrowth Phase of Intermittent Androgen Ablation Therapy in Patients with Advanced Prostate Cancer. Co-Investigator.
4. CALGB 90202: A Randomized, Double-Blind, Placebo-Controlled, Phase III Study Of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men With Prostate Cancer Metastatic to Bone. Co-Investigator.
5. Phase I/II Trial of Anti-IGF-IR Monoclonal Antibody IMC-A12 plus mTOR inhibitor temsirolimus in metastatic castration-resistant prostate cancer (CRPC). Co-Investigator.
6. Randomized, Double-Blind, Phase 3 Trial to Compare the Efficacy of Ipilimumab vs Placebo in Asymptomatic or Minimally Symptomatic Patients with Metastatic Chemotherapy-Naive Castration Resistant Prostate Cancer. Local PI.
7. A Phase II study of Abiraterone acetate in Patients with Castration Resistant Prostate Cancer (CRPC) and Prior Therapy with Ketoconazole. Local PI.
8. A randomized, double-blind, placebo-controlled, multicenter phase II trial investigating 2 doses of EMD 525797 in subjects with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer (mCRPC). Co-Investigator.
9. A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs Placebo Following Radiotherapy in Subjects with Castration Resistant Prostate Cancer That Have Received Prior Treatment with Docetaxel. Local PI.
10. A randomized phase 2.5 study of <sup>153</sup>Sm-EDTMP (Quadramet) with or without a PSA/TRICOM vaccine in men with androgen-insensitive metastatic prostate cancer. Local PI.
11. A phase I, open-label study of the safety and pharmacokinetics of escalating doses of DSTP3086S in patients with metastatic castration-resistant prostate cancer. Co-Investigator.
12. A phase III study of docetaxel +/- enzastaurin. Local PI.
13. A Multicenter, Randomized, Double Blind Study Comparing the Efficacy and Safety of Afibercept Versus Placebo Administered Every 3 Weeks in Patients Treated With Docetaxel/ Prednisone for Metastatic Androgen-independent Prostate Cancer. Local PI.
14. An Open-Label, Phase II Safety, Tolerability, Drug Level and Efficacy Trial of Quinacrine in Patients With Androgen-Independent Prostate Cancer. Local PI.
15. Phase 1/2, Open-Label, Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of TAK-700 in Metastatic, Androgen-Independent Prostate Cancer Subjects. Co-Investigator.
16. AFFIRM: A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based. Local PI (University of Chicago).
17. A pilot study of bone marrow biopsy in men with advanced prostate cancer. PI (University of Chicago)
18. A Randomized Discontinuation Phase 2 Study of AZD0530 as a Metastasis Inhibitor in Castrate Resistant Prostate Cancer. CTEP/DOD PCCTC supported IST initiated at University of Chicago- Overall PI
19. A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects with Castration Resistant Prostate Cancer That Have Received Prior Treatment with Docetaxel. Local PI.
20. PAK1 is downstream of Fyn and impacts growth and motility. Laboratory research supported by DoD and PCF grants
21. Genetic variation in Fyn impacts the growth and motility of prostate cancer cells. Laboratory work supported by PCF.
22. Role of Fyn in the epithelial-to-mesenchymal transition in prostate cancer. Collaboration with Beatrice Knudsen (CSMC) and Amanda Walker (Johns Hopkins)
23. Regulation of microenvironmental interactions in prostate cancer by XL184 (cabozantinib): Co-investigator on PCF grant with Leland Chung (CSMC).

24. Understanding the biology of XL184 in men with castrate resistant prostate cancer using treatment science. PCF sponsored phase II study at UCSF, U Washington, and CSMC. Local PI, co-investigator on PCF grant.
25. S0925: Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer. SWOG study being activated at CSMC. Local PI.
26. National Pro-active Surveillance Network for Prostate Cancer. Co investigator. PCF sponsored study at CSMC and Johns Hopkins.
27. A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy. Local PI
28. Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) With a GNRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT With a GNRH Agonist and TAK-700 For Men With High Risk Prostate Cancer. Co-investigator
29. A pilot study of circulating tumor cell collection using a near-infrared heptamethine cyanine dye in combination with a nanofluidic device. Principal Investigator.
30. An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer. Local PI

### **Active**

1. FYN: a regulator of motility and metastasis in prostate cancer. Laboratory research supported by DoD and PCF grants
2. A phase II study of cabozantinib in metastatic, castrate-resistant prostate cancer with visceral metastases. Principal Investigator.
3. A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer. Local PI
4. The Men's Eating and Living (MEAL) Study: A Randomized Trial of Diet to Alter Disease Progression in Prostate Cancer Patients on Active Surveillance. Co-investigator
5. A phase I study of abiraterone + ARN-509 in castration-resistant prostate cancer. Local PI
6. Phase II Randomized, Placebo-Controlled Trial of PROSTVAC (PSA-TRICOM) in Patients With Clinically Localized Prostate Cancer Undergoing Active Surveillance. Consortium PI and local co-investigator
7. Phase Ib, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN-509 in Combination With Abiraterone Acetate in Patients With Metastatic Castrate Resistant Prostate Cancer (CRPC). Local PI
8. A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination with Abiraterone Acetate & Prednisone vs Abiraterone Acetate and Prednisone in Subjects with Chemotherapy-naive (mCRPC). Local PI.
9. CAPS2: A Randomized controlled clinical trial of carbohydrate restriction among men with a rising PSA after failed primary therapy for prostate cancer. Co-investigator
10. A feasibility study for the enumeration and characterization of circulating tumor cells in prostate cancer. Principal Investigator
11. A prospective study of vsnCTC as predictive markers for visceral metastasis in PCa. Principal Investigator
12. Circulating Cell and Extracellular Vesicle Biobanking and Analysis in Cancer. Principal Investigator

### **Renal Cancer**

#### **Past:**

1. A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of pazopanib as adjuvant therapy for subjects localized or locally advanced RCC following nephrectomy. Co-Investigator (Here at CSMC).
2. CALGB 90802: Randomized Phase III Trial Comparing Everolimus Plus Placebo Versus Everolimus Plus Bevacizumab For Advanced Renal Cell Carcinoma Progressing After Treatment With Tyrosine Kinase Inhibitors. Co-Investigator.
3. An open-label, randomized, multi-center, Phase III study to compare the safety and efficacy of TKI258 versus sorafenib in patients with metastatic renal cell carcinoma after failure of anti-angiogenic (VEGF-targeted and mTOR inhibitor) therapies. Co-Investigator.
4. A Randomized Phase II Study of Afinitor (RAD001) vs. Sutent (Sunitinib) in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN). Co-Investigator.
5. A Phase II dose ranging study of BMS-936558 (MDX1106) in kidney cancer patients whose cancer is growing after treatment with angiogenesis therapy. Co-investigator

6. VEG113387: A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of pazopanib as adjuvant therapy for subjects with localized or locally advanced Renal Cell Carcinoma following nephrectomy. Co-investigator
7. A Randomized, Controlled Phase III Study Investigating IMA901 Multi-peptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma. Co-investigator

**Active:**

1. EVEREST: EVERolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study. Co-investigator
2. A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects With Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma. Co-investigator
3. A Randomized, Open-Label, Phase 3 Study of Nivolumab (BMS-936558) vs. Everolimus in Subjects With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy. Co-investigator
4. A Randomized, Phase 2 Study to Assess the Safety and Efficacy of CRLX101 in Combination With Bevacizumab in Patients With Metastatic Renal Cell Carcinoma (RCC) Versus Standard of Care (SOC) (Investigator's Choice). Co-investigator
5. A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy. Co-investigator
6. A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone (Including a lead-in Phase 1B Dose Escalation Portion) in Patients With Advanced or Metastatic Renal Cell Carcinoma. Local-PI
7. A Phase 1, Multiple-Dose, Dose-Escalation Trial of PT2385 Tablets, a HIF-2A Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma. Co-investigator
8. A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma. Co-investigator
9. An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS 003) Plus Standard Treatment of Advanced Renal Cell Carcinoma. Co-investigator

**Bladder**

**Past:**

1. Identification of Genetic Determinants of Response to Neoadjuvant Cisplatin-Based Chemotherapy in Urothelial Cancer. Co-Investigator.
2. CALGB 90601: A randomized double-blinded phase III study comparing gemcitabine, cisplatin, and bevacizumab (IND #7921, NSC #704865) to gemcitabine, cisplatin, and placebo in patients with Advanced transitional cell carcinoma. Co-Investigator.
3. A Phase I/II Study of E7389 Halichondrin B Analog (NSC #707389) in Metastatic Urothelial Tract Cancer and Renal Insufficiency. Co-Investigator.
4. Gemcitabine and cisplatin with or without OGX-427 in unresectable or metastatic urothelial CA. Local PI

**Active:**

1. A Phase II Protocol for Patients With Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent With Radiosensitizing Chemotherapy Following a Thorough Transurethral Surgical Re-Staging. Co-investigator

## Lectures/Presentations:

1. Proteomic analysis for detection and individualization of ovarian cancer treatment. Ovarian Cancer Coalition of the Greater Washington Area. Washington, DC. Sept 8, 2003.
2. Serum Proteomic Approaches for Diagnosis of Ovarian Cancer. 3rd annual Breast Cancer Congress. South Hampton, Bermuda. July 2004.
3. Proteomics and cancer: from bench to bedside to bench to bedside. Inland National Cancer Consortium Annual Conference. Spokane, WA. November 2004- Keynote Lecture
4. Proteomics applications for ovarian cancer. Gynecologic Oncology GMT Conference- Memorial Sloan Kettering Cancer Center. January 21, 2005
5. Proteomics and new screening techniques in ovarian cancer. Women and Cancer: Questions and Answers- Memorial Sloan Kettering Cancer Center. March 31, 2005
6. Clinical Applications of Proteomics. Makati Medical Center Scientific Symposium/Grand Rounds. October 10, 2006.
7. The Rising PSA Syndrome. Association of VA Hematology/Oncology Annual Meeting 2008.
8. Management of Advanced Bladder Cancer. Genitourinary Oncology Teaching Series- Physician Education Resources 2008.
9. Management of Hormone Refractory Prostate Cancer. Alexian Brothers Oncology Education Series November 8, 2009.
10. Advances in Systemic Therapy for Prostate Cancer. University of Chicago- Department of Medicine Grand Rounds. March 23, 2010.
11. Advances in Prostate Cancer. Cedars-Sinai Medical Center Oncology Rounds. Sept 5, 2010
12. Immunotherapy in Prostate cancer. University of Chicago Translational Sciences Symposium October 10, 2010.
13. Updates in Systemic Therapy for Prostate Cancer. - Physician Education Resources 2010
14. Management of Hormone Refractory Prostate Cancer. Chicago Urologic Society Symposium. December 1, 2010
15. Prostate Cancer Cure: How to do we get there? Healthcare College- Board of Governernors, Cedars-Sinai Medical Center- May 3, 2011
16. Targeted Therapy in Prostate Cancer- April 25, 2011
17. Advanced In Renal Cell Carcinoma- June 9, 2011
18. Management of high-risk prostate cancer, ASTRO 2011 August 5, 2011 Miami, FL
19. Updates in Systemic Therapy for Prostate Cancer. Pathology Grand Rounds, Cedars-Sinai Medical Center, August 26, 2011
20. A patient with metastatic-castrate resistant prostate cancer treated with cabozantinib. Expert Forum on MET (CTEP supported). October 21, 2011.
21. Prostate Cancer Therapy in 2011. Medicine Grand Rounds, CSMC 2011
22. Multidisciplinary care in prostate cancer: the medical oncologists perspective. CSMC Multi-disciplinary Cancer Management Program. Spring 2012.
23. Clinical Trials vs. Standard Care: Exploring New Approaches in Cancer Treatment. ACS Doc Talks. September 18, 2012
24. Prostate Cancer Care in the Elderly. First Annual Symposium on the Treatment of Elderly Patients with Cancer. BioMedical Learning Institute. Los Angeles. October 13, 2012.
25. Therapeutic Advances in Prostate, Kidney, and Bladder Cancer. New Therapeutics in Oncology: The Road to Personalized Medicine. CSMC. October 2012.
26. Advances in Systemic Therapy for Prostate and Kidney Cancer. Special Lecture/Heme-Onc Grand Rounds- Siriraj Hopital/Mahidol University, Bangkok, Thailand- Sept 5, 2013
27. Targeting the c-MET pathway: Clinical Applications. New Therapeutics in Oncology: The Road to Personalized Medicine. CSMC November 9, 2013
28. Management of Testicular Cancer in 2013. Hematology Oncology Grand Rounds. SOCCI/CSMC November 18, 2013
29. CTC technology in solid tumors. 10th World Congress on Urologic Research. Society of Basic Urologic Research / European Society for Urologic Research. Nashville, TN. November 21, 2013
30. Advances in Detection and Treatment of Prostate Kidney, and Bladder Cancer. Healthcare Innovations Conference. Guam Medical Association. Guam. October 5, 2013
31. Molecular analysis of circulating tumor cells in prostate cancer: moving toward a liquid biopsy and personalized medicine. UCLA Mathematics Forum. February 10, 2014
32. Targeting metastasis in prostate cancer: Fyn and circulating tumor cells. Grand Rounds, City of Hope. April 8, 2014
33. Clinical perspectives in Translational Research. CSMC-Clinical Translational Research Workshop, July 2, 2014
34. Early Detection and Management of Prostate Cancer. Guam Medical Association. October 18, 2014
35. Advances in Prostate Cancer therapy. XY Congress - Male and Female Cancer Research and Drug. November 6, 2014



36. Prostate Cancer in African-American Men: What You Need to Know. Holman Methodist Church Men's Health Forum. November 8, 2014
37. Targeted therapy in Renal Cell Carcinoma. Kidney Cancer Association. February 7, 2015
38. Multidisciplinary Care in Prostate Cancer. Huntington Hospital. March 3, 2015
39. Immunotherapy of Genitourinary Malignancies. Advances in Cancer Immunotherapy- Society of Immunologic Therapy for Cancer. Los Angeles, CA. June 19, 2015
40. Circulating tumor cell nuclear sizes predict visceral metastasis in prostate cancer patients. Urologic Association of Asia/ Chinese Urologic Association Annual Meeting. Shanghai, China. Sept 5, 2015
41. Intermittent vs. Continuous Androgen Deprivation Therapy. Hormone Therapy in Cancer Treatment. Ho Chi Minh City/Hanoi, Vietnam. May 14-15, 2016

### **CSMC Teaching Activities**

1. Oncology Inpatient Consultation Service Attending (1 month annually)
2. What happens when prostate cancer metastasizes? CSMC/SOCCI Men's Health Conference. April 26, 2014
3. Management of BRCA-associated prostate cancer. Advances in Care for the New Millennium: 20th Anniversary BRCA Gene Symposium. CSMC. Sept 13, 2014
4. Advancing Paradigms in Systemic Therapy for prostate cancer. Department of Surgery Urology Grand Rounds. February 5, 2015
5. Molecular Targets in Kidney and Bladder Cancer. CSMC Experimental Therapeutics Conference. March 7, 2015
6. Advances in Medical Therapy for Prostate Cancer. Cancer Journal Club/Grand Rounds. Charles Drew University. July 12, 2015
7. Urologic Oncology for OCNs. June 18, 2015
8. Circulating tumor cells versus circulating tumor DNA. Experimental Therapeutics in Oncology: The Road to Personalized Medicine. Los Angeles, CA. October 23-24, 2015
9. Blood-based biomarkers and precision oncology. Hematology/Oncology Grand Rounds. Samuel Oschin Comprehensive Cancer Institute. Los Angeles, CA. May 10, 2016.

### **Mentored Students And Trainees**

1. Chiara Pazzagli, PhD- Universita di Firenze- Summer NIH Student 2004 – Post-doctoral fellow- Università di Firenze, Dipartimento di Dermatologia
2. Meghan Liel, M.D.- Graduate-Duke University School of Medicine- NIH Clinical Research Training Program- 2004-2005 (\* CCR-FYI Travel award won among pool of post-doctoral researchers.): Residency: Oregon Health Sciences; Oncology Fellow- OHSU. Hematologist- Denver, CO.
3. Yoshi Saito, M.D.- University of Chicago (Graduated 2009); Medicine Resident- University of Hawaii (Won Fetness Fellowship for laboratory research). October 2008-May 2009. Fellow- Ohio State University Hematology/Oncology 2014
4. Ellis Kim (2010-2011)- University of Chicago (BS,MD); recipient of Katen's Scholar 2010. Honors thesis mentee for BS in Chemistry. Medical Student- University of Chicago Class of 2015. Resident
5. Hyewon Won (2010-2011)- University of Chicago (May 2012- BS Biology); honors thesis mentee. MD student- Tufts University (hyewonwon@gamil.com)
6. Alan Sit (Summer 2010)- University of Chicago undergrad- Boston University School of Medicine Class of 2015
7. Lucy Wagala- Young Scientist Training Program Participant (Summer 2010)- Undergraduate, Villinova Univ.
8. Amanda Walker, M.D. (2010)- Medicine Intern (prelim) continuing to Johns Hopkins Radiation Oncology Residency
9. Olwen Hahn, M.D. – Assistant Professor, University of Chicago (2005-2006)
10. Kathryn Bylow, M.D.- Assistant Professor, Medical College of Wisconsin (2005-2006)
11. David Knight, M.D.-Ph.D.- Private practice- Pleasant Prarie (2006-2009)
12. Syed Ahmed, M.D.-Ph.D.- Private practice- Schaumburg, IL (2006-2009)
13. Justine Yang Bruce, M.D.- Assistant Professor, University of Wisconsin (2007-2010)
14. Richard Lee, M.D.- Assistant Professor, M.D. Anderson Cancer Center (2007-2010)
15. Russell Szmulewitz, M.D.- Assistant Professor, University of Chicago (2007 – current)
16. Peter O'Donnell, M.D.- Assistant Professor, University of Chicago (2007-2011)
17. Ana Jensen, M.D.- Laboratory student (2008-2009); Resident- Internal Medicine. Seattle, WA
18. James Ward, M.D. 2009-2011- Instructor, University of Chicago (2009-2011); Asst. Prof. Univ. Of Calif, Irvine
19. Justin Levy - High School Student (Summer 2012)
20. Eric Brunner- High school student mentee (2014)- Undergraduate- University of Chicago
21. Christian Vazquez- High school student mentee (2014)- Undergraduate- Harvard University
22. Yi-Tsung (John) Lu, MD – Post Doctoral Researcher, Cedars Sinai Medical Center (2012-2014); Residency: internal Medicine- Cook County Hospitals, Chicago, IL
23. Jake Lichterman (2012-2013)- DO candidate- New York Osteopathic Medical College
24. Jeff Chen, MD- Post-doctoral fellow (2014-current)

25. Shaleekha Sharma (2012-current)
26. Julie Yang (2012- Current )- PhD candidate- Cancer Biology, CSMC
27. Shawn Wagner, PhD- (2014-current) Faculty translational mentor
28. Elisabeth Hodara (2014-2016)- Medical Student: Sackler School of Medicine (2016)
29. Elizabeth Kaufman (2014- current)- medical student University of Southern California
30. Rafi Ahmed, MD (2013-2015)- Medical Oncologist, Kaiser Permanente
31. Richard Hyunh, MD (2014-2016)- Medical Oncology Fellow- Cedars-Sinai
32. Shirley Cheng (2015-Current)-
33. Alexander Montes (2015-Current)-
34. Kenneth Steadman, MS (2015- Current)- PhD candidate- Cancer Biology, CSMC
35. Anisha Madhav (2016-Current)- PhD candidate- Cancer Biology, CSMC

## **BIBLIOGRAPHY/PUBLICATIONS:**

### **RESEARCH PAPERS (PEER REVIEWED)**

#### A. RESEARCH PAPERS - PEER REVIEWED

1. Dahiyat, B. I., Hostin, E., **Posadas, E. M.** and Leong, K. W. "Synthesis and characterization of putrescine-based poly(phosphoester-urethanes)." Journal of biomaterials science. Polymer edition 4: 529-543 (1993). PMID:8241068
2. **Posadas, E. M.**, Criley, S. R. and Coffey, D. S. "Chaotic oscillations in cultured cells: rat prostate cancer." Cancer research 56: 3682-3688 (1996). PMID:8706008
3. Leonard, G. D., **Posadas, E.**, Herrmann, P. C., Anderson, V. L., Jaffe, E. S., Holland, S. M. and Wilson, W. H. "Non-Hodgkin's lymphoma in Job's syndrome: a case report and literature review." Leukemia & lymphoma 45: 2521-2525 (2004). PMID:15621772
4. **Posadas, E. M.**, Gulley, J., Arlen, P. M., Trout, A., Parnes, H. L., Wright, J., Lee, M. J., Chung, E. J., Trepel, J. B., Sparreboom, A., Chen, C., Jones, E., Steinberg, S. M., Daniels, A., Figg, W. D. and Dahut WL "A phase II study of perifosine in androgen independent prostate cancer." Cancer biology & therapy 4: 1133-1137 (2005). PMID:16138006
5. **Posadas, E. M.**, Kwitkowski, V., Kotz, H. L., Espina, V., Minasian, L., Tchabo, N., Premkumar, A., Hussain, M. M., Chang, R., Steinberg, S. M. and Kohn EC "A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling." Cancer 110: 309-317 (2007). PMID:17559139
6. **Posadas, E. M.**, Liel, M. S., Kwitkowski, V., Minasian, L., Godwin, A. K., Hussain, M. M., Espina, V., Wood, B. J., Steinberg, S. M. and Kohn EC "A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer." Cancer 109: 1323-1330 (2007). PMID:17330838
7. **Posadas, E. M.\***, Undevia, S., Manchen, E., Wade, J. L., Colevas, A. D., Karrison T, Vokes EE and Stadler, W. M. "A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma." Cancer biology & therapy 6: 490-493 (2007). PMID:17457044
8. Azad, N. S., **Posadas, E. M.**, Kwitkowski, V. E., Steinberg, S. M., Jain, L., Annunziata, C. M., Minasian, L., Sarosy, G., Kotz, H. L., Premkumar, A., Cao, L., McNally, D., Chow, C., Chen, H. X., Wright, J. J., Figg, W. D. and Kohn EC "Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 26: 3709-3714 (2008). PMID:18669456
9. Dahut WL, Scripture, C., **Posadas, E.**, Jain, L., Gulley, J. L., Arlen, P. M., Wright, J. J., Yu, Y., Cao, L., Steinberg, S. M., Aragon-Ching, J. B., Venitz, J., Jones, E., Chen, C. C. and Figg, W. D. "A phase II clinical trial of sorafenib in androgen-independent prostate cancer." Clinical cancer research : an official journal of the American Association for Cancer Research 14: 209-214 (2008). PMID:18172272
10. Bylow, K. A., Atkins, M. B., **Posadas, E. M.**, Stadler, W. M. and McDermott, D. F. "Phase II trial of carboplatin and paclitaxel in papillary renal cell carcinoma." Clinical genitourinary cancer 7: 39-42 (2009). PMID:19213667
11. Lara, P. N., Jr., Longmate, J., Evans, C. P., Quinn, D. I., Twardowski, P., Chatta, G., **Posadas, E.**, Stadler, W. and Gandara, D. R. "A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study." Anti-cancer drugs 20: 179-184 (2009). PMID:19396016
12. **Posadas, E. M.\***, Al-Ahmadie, H., Robinson, V. L., Jagadeeswaran, R., Otto, K., Kasza, K. E., Tretiakov, M., Siddiqui, J., Pienta, K. J., Stadler, W. M., Rinker-Schaeffer, C. and Salgia, R. "FYN is overexpressed in human prostate cancer." BJU international 103: 171-177 (2009). PMID:18990162

13. Szmulewitz, R., Mohile, S., **Posadas, E.**, Kunnavakkam, R., Karrison T, Manchen, E. and Stadler, W. M. "A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer." European urology 56: 97-103 (2009). PMID:19282098
14. Yu, E. Y., Wilding, G., **Posadas, E.**, Gross, M., Culine, S., Massard, C., Morris, M. J., Hudes, G., Calabro, F., Cheng, S., Trudel, G. C., Paliwal, P. and Sternberg, C. N. "Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer." Clinical cancer research : an official journal of the American Association for Cancer Research 15: 7421-7428 (2009). PMID:19920114
15. Chung, E. K., **Posadas, E. M.**, Kasza, K., Karrison T, Manchen, E., Hahn, O. M. and Stadler, W. M. "A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Carcinoma." American journal of clinical oncology 34(2):150-4 (2010). PMID:20395787
16. O'Donnell, P. H., Jensen, A., **Posadas, E. M.**, Bridge, J. A., Yeldandi, A. V., Yang, X. J., Stadler, W. M. and Al-Ahmadie, H. "Renal medullary-like carcinoma in an adult without sickle cell hemoglobinopathy." Nature reviews. Urology 77: 110-114 (2010). PMID:20145663
17. Jensen, A. R., Saito, Y. D., Liao, C., Dai, J., Keller, E. T., Al-Ahmadie, H. A., Dakin Hache, K., Usatyuk, P., Sievert, M. F., Paner, G., Yala, S., Cervantes, G. M., Natarajan, V., Salgia, R. and **Posadas, E. M.\***, "Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cells." Clinical cancer research: an official journal of the American Association for Cancer Research (2011). PMID:21364031
18. Sajid, S., Mohile, S.G., Szmulewitz, R., **Posadas, E.**, Dale, W., "Individualized decision-making for older men with prostate cancer: balancing cancer control with treatment consequences across the clinical spectrum." Semin Oncol 38:309-25 (2011). PMID:21421119
19. Yu, E.Y., Massard C., Gross M.E., Carducci M.A., Culine S., Hudes G., **Posadas E.M.**, Sternberg CN, Wilding G, Trudel GC, Paliwal P, Fizazi K. "Once-daily Dasatinib: Expansion of Phase II Study Evaluating Safety and Efficacy of Dasatinib in Patients With Metastatic Castration-resistant Prostate Cancer." Urology 77: 1166-77 (2011). PMID:21539969
20. Araujo, J.C., Mathew, P., Armstrong, A.J., Braud, E.L., **Posadas, E.**, Lonberg, M., Gallick, G.E., Trudel, G.C., Paliwal, P., Agrawal, S., Logothetis, C.J., "Dasatinib Combined With Docetaxel for Castration-Resistant Prostate Cancer". Cancer (2011). PMID:21976132
21. Ward, J.E., Karrison T, Chatta, G., Hussain, M., Shevrin, D., O'Donnell P, Szmulewitz, R.Z., Stadler, W.M., **Posadas, E.M.\***, "A randomized phase II study of pazopanib in castrate sensitive prostate cancer: a University of Chicago Phase II Consortium/ Department of Defense Prostate Cancer Clinical Trials Consortium study." Prostate Cancer Prostatic Dis. 2012 Mar;15(1):87-92 PMID:22006050
22. Tannir N.M., Wong Y., Kollmannsberger C.K., Ernstoff M.S., Perry D.J., Appleman L.J., **Posadas E.M.**, Cho D., Choueiri T.K., Coates A., Gupta N., Pradhan R., Qian J., Chen J., Scappaticci F., Ricker J.L., Carlson D.M., Michaelson MD "Phase 2 Trial of Linifanib (ABT-869) in Patients with Advanced Renal Cell Cancer (RCC) after Sunitinib Failure." Eu J Cancer 47:2706-14 (2011) PMID:22078932
23. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS; AFFIRM Investigators, "Increased survival with enzalutamide in prostate cancer after chemotherapy", N Engl J Med. 367:1187-97 (2012) PMID:22894553
24. **Posadas, E.M.**, Figlin RA, "Understanding the role of MET kinase in cancer therapy", J Clin Oncol. 31(2):169-70. 2013 Jan 10. PMID: 23213104
25. Antonarakis, E.S, Heath, E.I., **Posadas, E.M.**, Yu, E.Y, Harrison, M.R., Bruce, J.Y., Cho, S.Y., Wilding, G.E., Fetterly, G.J., Hangauer, D.G., Kwan, M.R., Dyster, L.M. Carducci, M.A. "A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer." Cancer Chemother Pharmacol. 2013 Jan 13. PMID:23314737
26. Zhao L, Lu YT, Li F, Wu K, Hou S, Yu J, Shen Q, Wu D, Song M, Ouyang WH, Luo Z, Lee T, Fang X, Shao C, Xu X, Garcia MA, Chung LW, Rettig M, Tseng HR, **Posadas EM**, "High-Purity Prostate Circulating Tumor Cell Isolation by a Polymer Nanofiber-Embedded Microchip for Whole Exome Sequencing", Adv Mater. (2013)[Epub ahead of print] PMID:23529932
27. Lu YT, Zhao L, Shen Q, Garcia MA, Wu D, Hou S, Song M, Xu X, Ouyang WH, Ouyang WW, Lichterman J, Luo Z, Xuan X, Huang J, Chung LW, Rettig M, Tseng HR, Shao C, **Posadas EM**, "NanoVelcro Chip for CTC enumeration in prostate cancer patients", Methods. (2013) [Epub ahead of print] PMID:23816790
28. Morello M, Minciocchi VR, de Candia P, Yang J, Posadas E, Kim H, Griffiths D, Bhowmick N, Chung LW, Gandellini P, Freeman MR, Demicheli F, Di Vizio D. Large oncosomes mediate intercellular transfer of functional microRNA. Cell Cycle. 2013 Nov 15;12(22):3526-36. doi: 10.4161/cc.26539. Epub 2013 Sep 23. PMID: 24091630
29. Shao C, Liao CP, Hu P, Chu CY, Zhang L, Bui MH, Ng CS, Josephson DY, Knudsen B, Tighiouart M, Kim HL, Zhou HE, Chung LW, Wang R, Posadas EM. Detection of live circulating tumor cells by a class of near-infrared heptamethine carbocyanine dyes in patients with localized and metastatic prostate cancer. PLoS One. 2014 Feb 14;9(2):e88967. doi: 10.1371/journal.pone.0088967. PMID: 24551200

30. Jossion S, Gururajan M, Hu P, Shao C, Chu CY, Zhau HE, Liu C, Lao K, Lu CL, Lu YT, Lichterman J, Nandana S, Li Q, Rogatko A, Berel D, Posadas EM, Fazli L, Sareen D, Chung LW. miR-409-3p/-5p promotes tumorigenesis, epithelial to mesenchymal transition and bone metastasis of human prostate cancer. *Clin Cancer Res*. 2014 Jun 24. PMID: 24963047
31. Jossion S, Gururajan M, Sung SY, Hu P, Shao C, Zhau HE, Liu C, Lichterman J, Duan P, Li Q, Rogatko A, Posadas EM, Haga CL, Chung LW. Stromal fibroblast-derived miR-409 promotes epithelial-to-mesenchymal transition and prostate tumorigenesis. *Oncogene*. 2014 Jul 28;0. doi: 10.1038/onc.2014.212. [Epub ahead of print] PMID: 25065597
32. Gururajan M, Jossion S, Chu GC, Lu CL, Lu YT, Haga CL, Zhau HE, Liu C, Lichterman J, Duan P, Posadas EM, Chung LW. miR-154\* and miR-379 in the DLK1-DIO3 MicroRNA Mega-Cluster Regulate Epithelial to Mesenchymal Transition and Bone Metastasis of Prostate Cancer. *Clin Cancer Res*. 2014 Dec 15;20(24):6559-69. doi: 10.1158/1078-0432.CCR-14-1784. Epub 2014 Oct 16. PMID: 25324143
33. Chen JF, Ho H, Lichterman J, Lu YT, Zhang Y, Garcia MA, Chen SF, Liang AJ, Hodara E, Zhau HE, Hous S, Ahmed RS, Luthringer DJ, Huang J, Li KC, Chung LWK, Ke Z, Tseng HR, **Posadas EM**. Subclassification of prostate cancer circulating tumor cells (CTCs) by nuclear size reveals very-small nuclear CTCs in patients with visceral metastases. *Cancer*. 2015 May 14. PMID: 25975562
34. Hahn NM, Knudsen BS, Daneshmand S, Koch MO, Bihrl R, Foster RS, Gardner TA, Cheng L, Liu Z, Breen T, Fleming MT, Lance R, Corless CL, Alva AS, Shen SS, Huang F, Gertych A, Gallick GE, Mallick J, Ryan C, Galsky MD, Lerner SP, **Posadas EM**, Sonpavde G. Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity. *Urol Oncol*. 2015 Sep 8. pii: S1078-1439 PMID: 26362343.
35. Hanyok BT, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, **Posadas EM**, Freedland SJ. Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database. *Cancer*. 2015 Oct 20. PMID: 26484853.
36. **Posadas EM**, Ahmed RS, Karrison T, Szmulewitz RZ, O'Donnell PH, Wade JL 3rd, Shen J, Gururajan M, Sievert M, Stadler WM. Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study. *Prostate*. 2015 Oct 23 PMID: 26493492.
37. Jiang R, Lu YT, Ho H, Li B, Chen JF, Lin M, Li F, Wu K, Wu H, Lichterman J, Wan H, Lu CL, OuYang W, Ni M, Wang L, Li G, Lee T, Zhang X, Yang J, Rettig M, Chung LW, Yang H, Li KC, Hou Y, Tseng HR, Hou S, Xu X, Wang J, **Posadas EM**. A comparison of isolated circulating tumor cells and tissue biopsies using whole-genome sequencing in prostate cancer. *Oncotarget*. 2015 Nov 5. doi: 10.18632/oncotarget.6330. [Epub ahead of print] PMID: 26575023
38. Gururajan M, Cavassani KA, Sievert M, Duan P, Lichterman J, Huang JM, Smith B, You S, Nandana S, Chu GC, Mink S, Jossion S, Liu C, Morello M, Jones LW, Kim J, Freeman MR, Bhomwick N, Zhau HE, Chung LW, **Posadas EM**. SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer. *Oncotarget*. 2015 Nov 26. doi: 10.18632/oncotarget.6398.
39. Tagawa ST, **Posadas EM**, Bruce J, Lim EA, Petrylak DP, Peng W, Kheoh T, Maul S, Smit JW, Gonzalez MD, De Porre P, Tran N, Nanus DM. Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer. *Eur Urol*. 2016 Feb 3. pii: S0302-2838(16)00130-5. doi: 10.1016/j.eururo.2016.01.028. [Epub ahead of print] PubMed PMID: 26852075.
40. **Posadas EM**, Figlin RA. Personalized Therapeutics and Value in Renal Cell Carcinoma: Moving Beyond Lines of Therapy. *J Oncol Pract*. 2016 May;12(5):424-5. doi: 10.1200/JOP.2016.012393. No abstract available. PMID: 27170689.
41. Chen JF, Zhu Y, Lu YT, Hodara E, Hou S, Agopian VG, Tomlinson JS, **Posadas EM**, Tseng HR. Clinical Applications of NanoVelcro Rare-Cell Assays for Detection and Characterization of Circulating Tumor Cells. *Theranostics*. 2016 Jun 15;6(9):1425-39. doi: 10.7150/thno.15359. eCollection 2016. Review. PMID: 27375790.
42. **Posadas EM**, Limvorasak S, Figlin RA. Third-Line Treatment Options for Kidney Cancer. *Oncology (Williston Park)*. 2016 Sep 15;30(9). pii: 218731

B. RESEARCH PAPERS - PEER REVIEWED (IN PRESS)

C. RESEARCH PAPERS - PEER REVIEWED (SUBMITTED)

## RESEARCH PAPERS (NON-PEER REVIEWED)

D. RESEARCH PAPERS – NON-PEER REVIEWED  
None

E. RESEARCH PAPERS – NON-PEER REVIEWED (IN PRESS)  
None

F. RESEARCH PAPERS – NON-PEER REVIEWED (SUBMITTED)  
None

## CHAPTERS

1. **Posadas, E.M.**, Dahut WL, Bladder Cancer in *Oncology-Hematology Source Book: Evidence-Based Principles* (1st ed.) Eds. Boyiadzis, Lebowitz, Frame, Fojo, 2007.
2. **Posadas, E.M.**, Kohn EC, "Chapter 4: tumor angiogenesis and metastasis." In *Principles and Practice of Gynecologic Oncology* (4th ed). Ed. W. Hoskins.
3. **Posadas, E.M.**, Kotz, H., Cervical Cancer. In *Bethesda Handbook of Clinical Oncology*. (2nd Ed.), 2005.
4. Simpkins, F., Espina, V., **Posadas, E.**, Petricoin, E., Liotta, L., Kohn EC, "Protein arrays for clinical proteomics and signal transduction profiling." Chapter 10 In *Proteomics in Cancer Research*. Ed D.C. Liebler, 2005.
5. **Posadas, E.M.**, Dahut WL, "Angiogenesis and Angiogenesis Inhibitors." In *The Molecular Oncology of Prostate Cancer*, eds. J Ross, C Foster, Jones and Bartlett, 2006.
6. Szmulewitz, R.Z., **Posadas, E.M.**, "Antiandrogen therapy in prostate cancer." *Update on Cancer Therapeutics*, doi:10.1016/j.uct.2007.10.003
7. Szmulewitz, R.Z., **Posadas, E.M.**, "Management of Prostate Cancer Bone Metastases." In *Prostate Cancer: A Clinical Guide*. Lippincott Williams & Wilkins, 2008.
8. Jensen, A.R., Szmulewitz, R.Z., Beer, T., **Posadas, E.M.**, "Calcitriol and Vitamin D analogs". *Drug Management of Prostate Cancer*. Eds. W. Figg and E. Small. 2010.
9. Kim, H.L., **Posadas, E.M.**, Figlin RA, "Presurgical Therapy for Renal Cell Carcinoma and Implications for Window of Opportunity Trials". *Renal Cell Carcinoma: Biology, Prognostic Factors, and Therapeutic targets*. 2011
10. Feng, F.Y., Chinnayan, A., **Posadas, E.M.**, "Molecular Biology of Prostate Cancer". *Principles and Practices of Oncology*. Eds. DeVita, Hellman, Rosenberg. 2014.

## LETTERS TO THE EDITOR

None

## REVIEWS

1. Sommerfeld, H.J., Meeker, A.K., **Posadas, E.M.**, Coffey, D.S., "Frontiers in Prostate Cancer: Telomeres and Cancer", *Cancer (supplement)*, 75(7): 2027-2035, 1995.
2. **Posadas, E.M.**, Dahut WL and Gulley, J. "The emerging role of bisphosphonates in prostate cancer." *American journal of therapeutics* 11: 60-73 (2004). PMID:14704597
3. **Posadas, E.M.**, Davidson, B. and Kohn EC "Proteomics and ovarian cancer: implications for diagnosis and treatment: a critical review of the recent literature." *Current opinion in oncology* 16: 478-484 (2004). PMID:15314519
4. **Posadas, E.M.\***, Simpkins, F., Liotta, L.A., MacDonald, C. and Kohn EC "Proteomic analysis for the early detection and rational treatment of cancer--realistic hope?" *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 16: 16-22 (2005). PMID:15598930
5. Stevens, E.V., **Posadas, E.M.**, Davidson, B. and Kohn EC, "Proteomics in cancer." *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 15 Suppl 4: iv167-171 (2004). PMID:15477302
6. Ghosh, L., Dahut WL, Kakar, S., **Posadas, E.M.**, Torres, C.G., Cancel-Santiago, R. and Ghosh, B.C., "Management of patients with metastatic cancer of unknown primary." *Current problems in surgery* 42: 12-66 (2005). PMID:15711508
7. Limvorasak, S., **Posadas E.M.\***, "Pazopanib: therapeutic developments." *Expert opinion on pharmacotherapy* 10: 3091-102 (2009). PMID:19954277
8. Limvorasak, S., **Posadas E.M.\***, "Kinase inhibitors in prostate cancer." *Anti-cancer agents in medicinal chemistry* 9: 1089-104 (2009). PMID:19925393
9. Saito YD., Jensen, A.R., Salgia, R., **Posadas, E.M.\***, "Fyn: a novel molecular target in cancer." *Cancer* 116: 1629-1637 (2010). PMID:20151426
10. Chen, T., **Posadas, E.**, Lukas, R., "Chemotherapy for Central Nervous System Metastases in Renal Cancer: A Review", *Kidney Cancer Journal* 9(2): 52-58 (2011)
11. **Posadas, E.M.**, Figlin RA, "Systemic Therapy in Renal Cell Carcinoma: Advancing Paradigms". *Oncology (Williston Park)*. 26(3):290-301 (2012) PMID:22545314
12. Gurujan, M.\* , **Posadas, E.M.\***, Chung, L.W.K., "Future perspectives of prostate cancer therapy." *Trans Androl and Urol. Trans Androl and Urol* 1:19-32 (2012) PMID:22773967
13. **Posadas EM**, Limvorasak S, Sharma S, Figlin RA. Targeting angiogenesis in renal cell carcinoma. *Expert Opin Pharmacother*. 2013 Nov;14(16):2221-36. doi: 10.1517/14656566.2013.832202. Epub 2013 Aug 28. PMID: 23984807.
14. **Posadas EM**, Figlin RA. Kidney cancer: progress and controversies in neoadjuvant therapy. *Nat Rev Urol*. 2014 May;11(5):254-5. PMID: 24752207

15. Chen JF, Zhu Y, Lu YT, Hodara E, Hou S, Agopian VG, Tomlinson JS, **Posadas EM**, Tseng HR. Clinical Applications of NanoVelcro Rare-Cell Assays for Detection and Characterization of Circulating Tumor Cells. *Theranostics*. 2016 Jun 15;6(9):1425-39. doi: 10.7150/thno.15359. eCollection 2016. PMID: 27375790
16. Kumbala RA, Figlin RA, **Posadas EM**. Recent Advances in the Medical Treatment of Recurrent or Metastatic Renal Cell Cancer. *Drugs*. 2016 Dec 19. Review. PMID: 27995579

## **EDITORIALS**

1. **Posadas EM**, Dahut W.L., "Approaches to inhibit invasiveness and metastasis in prostate cancer." *Clinical prostate cancer* 1: 125 (2002). PMID:15046704
2. O'Donnell P.H., **Posadas EM**, "Editorial comment." *Urology* 77: 165-6 (2011). PMID:21195839

## **RESEARCH PAPERS- IN PREPARATION**

1. Hodara E, Kaufman E, Posadas EM. Biology of visceral metastatic lesions in prostate cancer.

## **ABSTRACTS**

1. **Posadas EM**, M. M. Hussain, Espina V, Kotz H, L. Minasian, S. M. Shreeve, A. Premkumar, L. A. Liotta, S. M. Steinberg, Kohn EC. A phase II clinical trial with proteomic profiling of imatinib mesylate in patients with refractory or relapsed epithelial ovarian cancer (EOC). *Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition)*. Vol 22, No 14S (July 15 Supplement), 2004: 9651.
2. Franks ME, **Posadas EM**, Macpherson, G., Dahut WL, Linehan, W.M., Price, D.K., Figg W.D., Leukapheresis of patients with androgen independent prostate cancer (AIPC) may enhance in vitro isolation of prostate cancer cells. *J Urol* 171: 104 (2004).
3. Kohn EC, **Posadas EM**, Espina V, V. Kwitkowski, B. Davidson, E.F. Petricoin, L. Liotta. Overview of proteomics with emphasis on diagnosis and monitoring. *EJC Supplements*, September 2004; (Vol. 2, Issue 8, Page 3)
4. **Posadas EM**, Gulley J, P. M. Arlen, N. Harold, S. Fioravanti, P. Meltzer, C. D. Scripture, W. D. Figg, Kohn EC, Dahut WL. A phase II study of BAY 43-9006 in patients with androgen-independent prostate cancer (AIPC) with proteomic profiling. *Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings*. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 4762.
5. Dahut W, **Posadas EM**, C. Scripture, Gulley J, P. Arlen, J. Wright, N. Harold, S. Fioravanti, W. Figg. A phase II study of BAY 43-9006 (sorafenib) in patients with androgen-independent prostate cancer (AIPC). *EJC Supplements*, October 2005; (Vol. 3, Issue 2, Page 248)
6. **Posadas EM**, V. Kwitkowski, M. Liel, Kotz H, L Minasian, G. Sarosy, N. Harold, S. Fioravanti, E. Kohn. Clinical Synergism from combinatorial VEGF signal transduction inhibition in patients with advanced solid tumors – early results from a phase I study of sorafenib (BAY 43-9006) and bevacizumab. *EJC Supplements*, October 2005; (Vol. 3, Issue 2, Page 419)
7. S. Wu, **Posadas EM**, C. Scripture, P. M. Arlen, J. L. Gulley, L. L. Latham, J. Wright, C. Chen, W. D. Figg, Dahut WL. BAY43-9006 (sorafenib) can lead to improvement of bone lesions in metastatic androgen-independent prostate cancer despite rises in serum PSA levels. abstract 259. 2006 Prostate Cancer Symposium.
8. Azad NS, **Posadas EM**, V. E. Kwitkowski, C. M. Annunziata, T. Barrett, A. Premkumar, H. L. Kotz, G. A. Sarosy, L. M. Minasian, Kohn EC. Increased efficacy and toxicity with combination anti-VEGF therapy using sorafenib and bevacizumab. *Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I*. Vol 24, No. 18S (June 20 Supplement), 2006: 3004.
9. **Posadas EM**, S. Undevia, A. D. Colevas, E. Manchen, Vokes EE, Stadler WM. A phase II study of ixabepilone (BMS 247550) in metastatic renal cell carcinoma. *Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I*. Vol 24, No. 18S (June 20 Supplement), 2006: 14646.
10. Dahut WL, C. D. Scripture, **Posadas EM**, S. Wu, P. M. Arlen, J. L. Gulley, J. Wright, C. C. Chen, E. Jones, W. D. Figg. Bony metastatic disease responses to sorafenib (BAY 43-9006) independent of PSA in patients with metastatic androgen independent prostate cancer. *Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I*. Vol 24, No. 18S (June 20 Supplement), 2006: 4506.
11. Knight DA, S. G. Mohile, **Posadas EM**, E. A. Manchen, Stadler WM. A phase I study of testosterone in patients (pts) with early castrate resistant prostate cancer (CRPC). *Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I*. Vol 25, No. 18S (June 20 Supplement), 2007: 15584.
12. Szmulewitz RZ, Tamara Lotan, Jennifer Taylor, Kay Maceod, Shaheena Khan, Nkechiyere Nwani, **Posadas EM**, Carrie Rinker-Schaeffer, and Interdepartmental Metastasis Research Group. Ectopic expression of JNKK1/MKK4 controls prostate cancer metastatic colonization by regulating growth of disseminated cancer cells. *AACR Meeting Abstracts*, Apr 2008; 2008: 2481.

13. Szmulewitz RZ, **Posadas EM**, B. Manchen, D. Knight, Stadler WM. A phase I study of testosterone for the treatment of hormone refractory prostate cancer. Abstract 201 2008 Genitourinary Cancers Symposium.
14. Yu EY, G. Wilding, **Posadas EM**, M. Gross, S. Culine, C. Massard, G. R. Hudes, S. Cheng, P. Paliwal, C. N. Sternberg. Dasatinib in patients with hormone-refractory progressive prostate cancer: A phase II study. Abstract 5156. 2008 ASCO Annual Meeting.
15. Szmulewitz RZ, Tamara Lotan, Jennifer Taylor, Kristen Otto, **Edwin M. Posadas**, Carrie W. Rinker-Schaeffer. Transient metastasis suppression by JNKK1/MKK4 in an experimental model of prostate cancer metastasis. Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract 1184.
16. Saito YD., Jensen, A.R., Otto, K., Faoro, L., Jagadeeswaran, R., Salgia, R., **Posadas EM**. FYN knockdown results in altered cell morphology and motility in prostate cancer. Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract 4654.
17. Tchabo, N.E., **Posadas EM**, Kotz, H.L., Minasian, L., Chang, R., Steinberg, S., Kohn EC, Proteomic profiling of tumor and stroma from ovarian cancer biopsies taken before and during imatinib treatment show a pharmacodynamic relationship between receptor phosphorylation and clinical toxicity. Proceedings of the 97th Annual Meeting of the American Association for Cancer Research; 2009 Abstract 5262.
18. Araujo J, P. Mathew, A.J. Armstrong, E.L. Braud, **Posadas EM**, M. Lonberg, G. Gallick, G.C. Trudel, P. Paliwal, C.J. Logothetis. Dasatinib and docetaxel combination treatment for patients with metastatic castration-resistant prostate cancer (CRPC): analysis of Study CA 180-086. European Journal of Cancer Supplements, Vol 7 No 2, September 2009, Page 415.
19. Tannir N, Y. Wong, C. Kollmannsberger, M.S. Ernstoff, D.J. Perry, L.J. Appleman, **Posadas EM**, J. Qian, J.L. Ricker, D.M. Michaelson. Phase 2 results of ABT-869 treatment in patients with advanced renal cell cancer (RCC) after sunitinib failure. European Journal of Cancer Supplements, Vol 7 No 2, September 2009, Page 425.
20. Tannir N, Y. Wong, C. Kollmannsberger, M. S. Ernstoff, D. J. Perry, L. J. Appleman, **Posadas EM**, J. Qian, J. L. Ricker, D. M. Michaelson. Phase II trial of ABT-869 in advanced renal cell cancer (RCC) after sunitinib failure: Efficacy and safety results. J Clin Oncol 27:15s, 2009 (suppl; abstr 5036)
21. Araujo J, A. J. Armstrong, E. L. Braud, **Posadas EM**, M. Lonberg, G. E. Gallick, G. C. Trudel, P. Paliwal, S. Agrawal, C. J. Logothetis. Dasatinib and docetaxel combination treatment for patients with castration-resistant progressive prostate cancer: A phase I/II study (CA180086). J Clin Oncol 27:15s, 2009 (suppl; abstr 5061)
22. Chung EK, **Posadas EM**, K. Kasza, T. Karrison, E. Manchen, L. Michalak, O. M. Hahn, Stadler WM. A phase II trial of gemcitabine(G), capecitabine I, and bevacizumab (B) in patients (pts) with metastatic renal cell carcinoma (RCC). J Clin Oncol 27, 2009 (suppl; abstr e16072)
23. Chung EK, **Posadas EM**, T. Karrison, E. Manchen, L. Michalak, O. M. Hahn, Stadler WM. A phase II trial of gemcitabine (G), capecitabine I and bevacizumab (B) in patients with metastatic renal cell carcinoma (RCC). 2009 Genitourinary Cancers Symposium.
24. Yu E, C. Massard, M. Gross, G. Wilding, **Posadas EM**, S. Culine, M. Carducci, G. Trudel (for the Research & Development, BMS), C. Sternberg. A phase II study of once-daily dasatinib for patients with castration-resistant prostate cancer (CRPC) (CA180085). Abstract 165 2009 Genitourinary Cancers Symposium.
25. Tannir NM, Y. Wong, C. K. Kollmannsberger, M. S. Ernstoff, D. J. Perry, L. J. Appleman, **Posadas EM**, J. Qian, J. L. Ricker, D. Michaelson. Phase II trial of linifanib in patients with advanced renal cell cancer (RCC) after sunitinib failure. J Clin Oncol 28:15s, 2010 (suppl; abstr 4527)
26. Szmulewitz RZ, **Posadas EM**, B. Manchen, Stadler WM. A randomized, double-blind, placebo-controlled phase II study of testosterone replacement in men with asymptomatic castrate-resistant prostate cancer (PC). J Clin Oncol 28:15s, 2010 (suppl; abstr TPS241)
27. Szmulewitz RZ, A. J. Wyche, **Posadas EM**, Stadler WM. Fluorescence-activated cell sorting (FACS) and immunofluorescence (IF) detection and characterization of circulating tumor cells (CTC) from men with castrate-resistant prostate cancer (CRPC). J Clin Oncol 29: 2011 (suppl 7; abstr 41)
28. Stein MN, I. Khan, M. Hussain, G. Liu, G. Wilding, **Posadas EM**, Stadler WM, C. Jeyamohan, S. Eddy, R. S. DiPaola. Phase II study of AT-101 to abrogate Bcl-2-mediated resistance to androgen-deprivation therapy (ADT) in patients (pts) with newly diagnosed androgen-dependent metastatic prostate cancer (ADMPC). J Clin Oncol 29: 2011 (suppl 7; abstr 137)
29. Ward JE, Karrison, T, Chatta G, Hussain M, Shevrin D, O'Donnell P, Szmulewitz RZ, Stadler WM, **Posadas EM**. A randomized phase II study of pazopanib in castrate-sensitive prostate cancer: A University of Chicago phase II consortium/DoD Prostate Cancer Clinical Trials Consortium study. J Clin Oncol, 29: 2011 (suppl 7; abstr 170)
30. **Posadas EM**, Tannir NM, Wong Y, Ernstoff MS, Kollmannsberger CK, Qian J, Ansell PJ, McKeegan EM, McKee MD, Ricker JL, Carlson DM, Michaelson MD. Phase II trial of linifanib in patients (pts) with



- advanced renal cell carcinoma (RCC): Analysis of pts receiving extended therapy. *J Clin Oncol* 29: 2011 (suppl; abstr 2543)
31. NM Hahn, S Daneshmand, **EM Posadas**, MO Koch, R Bihrl, R Foster, TA Masterson, L Cheng, Z Liu, T Breen, MT Fleming, R Lance, CW Ryan, CL Corless, MD Galsky, A Shivaram Alva, C Mitchell, SS Shen, SP Lerner, G Sonpavde. A phase II trial of neoadjuvant dasatinib (Neo-D) in muscle-invasive urothelial carcinoma of the bladder (miUCB): Hoosier Oncology Group GU07-122 trial. *J Clin Oncol* 30, 2012 (suppl; abstr 4586).
  32. NM Hahn, S Daneshmand, **EM Posadas**, MO Koch, R Bihrl, R Foster, TA Masterson, L Cheng, Z Liu, T Breen, MT Fleming, R Lance, CW Ryan, CL Corless, MD Galsky, A Shivaram Alva, C Mitchell, SS Shen, SP Lerner, G Sonpavde. ; Biologic activity of dasatinib administered as neoadjuvant therapy preceding radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC). *J Clin Oncol* 32, 2014 (suppl 4; abstr 324)
  33. Choueiri TK, Michaelson MD, **Posadas EM**, Sonpavde G, McDermott DF, Walsh MK, Wall KC, Seon BK, Jivani MA, Adams BJ, Theuer CP. A phase 1b dose-escalation study of TRC105 (anti-endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma (mRCC). *J Clin Oncol* 32, 2014 (suppl; abstr e15562)
  34. Tagawa ST, **Posadas EM**, Bruce J, Lim EA, Petrylak DP, Ping W, Kheoh T, Maul S, Smit JW, Gonzalez MD, Deporre P, Tran N, Nanus DM Phase 1b study of abiraterone acetate (AA) and docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). *J Clin Oncol* 32:5s, 2014 (suppl; abstr 5025)
  35. **Posadas EM**, Tighiouart M, Lu Y, Di Vizio D, Hoffman DJ, Green L, Scher K, Sievert M, Oppenheim A, Moldawer N, Knudsen B, Freeman M, Bhowmick N, Rogatko A, Tseng HR, Chung LWK, Figlin RA. A translational phase 2 study of cabozantinib in men with metastatic castration resistant prostate cancer with visceral metastases with characterization of circulating tumor cells and large oncosomes. *J Clin Oncol* 32, 2014 (suppl; abstr e16080)
  36. **Posadas EM**, Tighiouart M, Lu Y, Di Vizio D, Hoffman DJ, Green L, Scher K, Sievert M, Oppenheim A, Moldawer N, Knudsen B, Freeman M, Bhowmick N, Rogatko A, Tseng HR, Chung LWK, Figlin RA. A translational phase 2 study of cabozantinib in men with metastatic castration resistant prostate cancer with visceral metastasis with characterization of circulating tumor cells and large oncosomes. *Annals of Oncology* 25 (Supplement 4): iv546–iv563, 2014
  37. Choueiri TK, Michaelson MD, **Posadas EM**, Sonpavde G, McDermott DF, Walsh MK, Wall KC, Seon BK, Jivani MA, Adams BJ, Theuer CP. A phase 1b dose-escalation study of TRC105 (anti-endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma. *J Clin Oncol* 33, 2015 (suppl 7; abstr 426)
  38. **Posadas EM**, Chi KN, De Wit R, Jonge MJ, Attard G, Friedlander TW, Yu MK, Hellemans, P, Chien C, Abrams CC, Gonzalez M, Trudel GC, Chauhan V, Jiao JJ, Saad F. Pharmacokinetics (PK) and safety of ARN-509 with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). *AACR 2015 Abstr CT302*
  39. Chen JF, Ho H, Lichterman J, Lu YT, Zhang Y, Garcia MA, Chen SF, Zhou H, Hous S, Ahmed RA, Luthringer DJ, Huang J, Li KC, Chung LWK, Ke Z, Tseng HR, **Posadas EM**. Sub-classification of prostate cancer circulating tumor cells (CTCs) by nuclear size reveals very-small nuclear CTCs in patients with visceral metastases. *AACR 2015 Abstr 3473*
  40. **Posadas EM**, Chi KN, De Wit R, Jonge MJ, Attard G, Friedlander TW, Yu MK, Hellemans, P, Chien C, Abrams CC, Gonzalez M, Trudel GC, Chauhan V, Jiao JJ, Saad F. Phase 1b study of ARN-509 with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). *J Clin Oncol* 33, 2015 (suppl; abstr 5028)
  41. Lu YT, Chen JF, Ho H, Lichterman J, Chung LWK, Li KC, Ke Z, Tseng HR, **Posadas EM**. Subclassification of prostate cancer circulating tumor cells (CTCs) by nuclear size reveals very-small nuclear CTCs in patients with visceral metastases. *J Clin Oncol* 33, 2015 (suppl; abstr 11027)
  42. Chen JF, Ho H, Hodara E, Go A, Ureno A, Kaufman ET, Sievert M, Chung LWK, Ke Z, Tseng HR, **Posadas EM**. Very small nuclear circulating tumor cell (vsnCTC) as a putative biomarker for visceral metastasis in metastatic castration-resistant prostate cancer (mCRPC). *J Clin Oncol* 34, 2016 (suppl 2S; abstr 64)
  43. Huynh R, Chen JF, Tighiouart M, Sievert M, Oppenheim A, Moldawer NP, Knudsen B, Freeman M, Bhowmick N, Rogatko A, Tseng HR, Cheng LWK, Scher K, Figlin RA, **Posadas EM**. A phase II study of cabozantinib in metastatic castration-resistant prostate cancer (mCRPC) with visceral metastases (VM) with very small nuclear circulating tumor cell (vsnCTC) association studies. *J Clin Oncol* 34, 2016 (suppl 2S; abstr 208)
  44. Autio KA, Garcia JA, Alva AS, Hart LL, Milowsky MI, **Posadas EM**, Ryan CJ, Summa JM, Yousoufian H, Scher HI, Dreicer R. A phase 2 study of BIND-014 (PSMA-targeted docetaxel nanoparticle) administered to patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC). *J Clin Oncol* 34, 2016 (suppl 2S; abstr 233)

45. Chen JF, Ho H, Hodara E, Ureno A, Go A, Kaufman E, Sievert M, Luthringer D, Huang J, Li KC, Ke Z, Chung L, Tseng HR, **Posadas E**. Very-Small-Nuclear Circulating Tumor Cell (vsnCTC) as a Putative Biomarker for Visceral Metastasis in Metastatic Castration-Resistant Prostate Cancer (mCRPC). AUA 2016
46. Chu GCY, Wang R, Zhau HE, **Posadas EM**, Chung LWK. Circulating tumor cells-derived patient xenografts: A novel approach to study prostate cancer lethal progression. AUA 2016

\* Edwin Posadas as corresponding author